NCT07463573 2026-03-11
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
Clinical Trials
56 trialsNCT06346392 2026-03-09
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT06356311 2026-02-27
TroFuse-015
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT01196390 2026-02-18
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT06752811 2026-02-10
pompom
Shanghai Yizhong Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT03801876 2026-01-14
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NRG Oncology
Phase 3 Recruiting
NCT04704934 2026-01-12
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Phase 3 Active not recruiting
NCT06644781 2026-01-12
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Daiichi Sankyo
Phase 3 Recruiting
NCT04949256 2025-12-15
MK-7902-014
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06914011 2025-12-03
MRD2START
Asan Medical Center
Phase 3 Not yet recruiting
NCT07262567 2025-12-03
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 3 Not yet recruiting
NCT03223376 2025-12-01
FRUTIGA
Hutchmed
Phase 3 Completed
NCT06304974 2025-11-17
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT04540211 2025-10-28
SKYSCRAPER-08
Hoffmann-La Roche
Phase 3 Completed
NCT03783442 2025-07-29
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT06793917 2025-07-20
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Fujian Cancer Hospital
Phase 3 Recruiting
NCT05357846 2025-06-12
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT03957590 2025-05-02
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT03085004 2025-04-17
CHARM
Milton S. Hershey Medical Center
Phase 3 Active not recruiting
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT02509286 2024-05-08
ESOPEC
University Hospital Schleswig-Holstein
Phase 3 Active not recruiting
NCT06123494 2024-01-16
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
NCT02178956 2023-11-15
BRIGHTER
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT03019588 2023-03-30
MK-3475-063
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT03933449 2023-03-29
KEYNOTE-181
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02564263 2023-03-13
KEYNOTE-181
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01726452 2022-09-30
NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)
Cancer Trials Ireland
Phase 3 Completed
NCT02569242 2022-07-06
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
Ono Pharmaceutical Co. Ltd
Phase 3 Completed
NCT05188313 2022-06-24
TRAP-2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 3 Recruiting
NCT00655876 2022-06-14
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT02898077 2022-06-14
A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
Eli Lilly and Company
Phase 3 Completed
NCT02370498 2022-06-06
MK-3475-061
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04807673 2022-06-01
KEYSTONE-002
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Recruiting
NCT02459457 2022-02-09
A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer
Fudan University
Phase 3 Completed
NCT04426955 2021-09-16
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT02934464 2021-09-13
ARMANI
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 3 Unknown
NCT02526953 2021-02-09
Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients
Blokhin's Russian Cancer Research Center
Phase 3 Unknown
NCT02625623 2020-11-24
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
EMD Serono
Phase 3 Completed
NCT01836432 2020-05-28
PILLAR
Lumos Pharma
Phase 3 Terminated
NCT01248403 2020-01-29
AIO-STO-0111
Krankenhaus Nordwest
Phase 3 Completed
NCT01170663 2019-09-18
RAINBOW
Eli Lilly and Company
Phase 3 Completed
NCT03308552 2019-01-02
Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02
ChineseAMS
Phase 3 Unknown
NCT03328234 2019-01-02
Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03
ChineseAMS
Phase 3 Unknown
NCT03731442 2018-12-12
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
ChineseAMS
Phase 3 Recruiting
NCT01591135 2018-10-18
A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma
Fudan University
Phase 3 Completed
NCT03475615 2018-03-23
A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites
Fudan University
Phase 3 Unknown
NCT03366883 2018-01-09
Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT02891083 2016-09-07
Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer
Shanghai Chest Hospital
Phase 3 Unknown